All Stories

Chutes & Ladders—Galapagos CEO eyes exit as spinout names leader

The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will retire from the top role within the next year, once a successor is found. Stoffels joined the company in 2022 after more than 13 years at Johnson & Johnson.

Apr 25, 2025 - 13:34
 0
Chutes & Ladders—Galapagos CEO eyes exit as spinout names leader
The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will retire from the top role within the next year, once a successor is found. Stoffels joined the company in 2022 after more than 13 years at Johnson & Johnson.
Read More

Tags:

Previous Article

At $14,000, Is This 1987 Puma GTC A Full Brazilian Bargain?

Next Article

EMEA-002282-PIP01-17-M02

Related Posts

Corcept's investigational oral therapy cuts ovarian cancer progression by 30%, teeing up FDA filing

Corcept's investigational oral therapy cuts ovarian can...

Mar 31, 2025  0

Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects

Biogen axes asset from $7.3B buyout, along with Alzheim...

Feb 12, 2025  0

From ADCs to radiopharma: How AstraZeneca is trying to 'redefine oncology care'

From ADCs to radiopharma: How AstraZeneca is trying to ...

Apr 10, 2025  0